Entecavir, alias entecavir hydrate and entecavir monohydrate, is currently the latest generation of drugs for the antiviral treatment of hepatitis B. At present, entecavir dispersible tablets have been fully localized, and four domestic pharmaceutical companies have obtained the approval number from the State Drug Administration and can carry out mass production. The following is a related analysis of the treatment effect of entecavir tablets, the effect of entecavir for hepatitis B: 1. Analysis of the antiviral treatment effect of entecavir tablets: Entecavir dispersible tablets have strong efficacy in inhibiting the replication of hepatitis B virus, and fast onset of action, in about three months to minimize the replication of the virus, entecavir antiviral effect is 300 times that of lamivudine. In a three-year clinical trial, 66 patients with chronic hepatitis B used entecavir tablets and 85% of the patients’ viral load was reduced to an unmeasurable level. 2, Entecavir resistance analysis: Entecavir not only has excellent antiviral effectiveness, but also has very low resistance, often as a remedial drug after lamivudine and adefovir resistance. A 5-drug resistance study done at the University of Tokyo showed that only about 1.2% of patients developed drug resistance in 5 years, which is tens of times lower compared to adefovir and lamivudine. 3, side effect analysis of entecavir: Entecavir as a western drug, some patients may experience clinical nausea, abdominal pain, diarrhea, abdominal discomfort, myalgia, ALT elevation, headache and dizziness, fatigue, vertigo, insomnia, rubella and indigestion. Patients should stop taking the medication after such conditions occur and accept the doctor’s instruction. Through the above analysis we can easily find that entecavir has an extremely strong efficacy in inhibiting viral replication and has the lowest drug resistance, with a relatively high price compared to lamivudine and adefovir.